Evidence Supporting Expansion of NCCN Guidelines of Germline Testing in Prostate Cancer
July 27th 2021Samantha E. Greenberg, MS, MPH, CGC, discusses if the changes to the National Comprehensive Cancer Network’s Clinical Practice Guidelines for Prostate Cancer. NCCN has expanded germline testing in metastatic prostate cancer to all patients with high-risk, very high-risk, or regional prostate cancer.
Watch
Exploring a Time-to-Relapse Analysis for Rituximab and Transplant in MCL
July 24th 2021Peter A. Riedell, MD, discusses the clinical implication of using frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation in patients with mantle cell lymphoma in an analysis of time to relapse.
Watch
Options for Second-Line Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
July 23rd 2021Dr Laurie Sehn reviews the NCCN guidelines for second-line therapy in relapsed/refractory diffuse large B-cell lymphoma and discusses the clinical trial data for a recently approved new treatment combination.
Watch